Payment overview · 2025
General Payments
$232.20
10 reported records · 5 companies
Healthcare provider profile · identity verified
Peter B Martens, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · MILTON, MA · NPI 1417981242
Verified facts
What the public records show
CMS Open Payments records show Peter B Martens, M.D. received $232.20 in general payments during 2025 across 10 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 43.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Enbrel by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $100.49 | 43.3% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $58.20 | 25.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.09 | 13.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $26.29 | 11.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.13 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $232.20 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $66.62 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 169 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 541 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 120 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 437 | 95 |
| Gabapentin | Gabapentin | 372 | 71 |
| Alendronate Sodium | Alendronate Sodium | 320 | 80 |
| Lisinopril | Lisinopril | 313 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 268 | 64 |
| Methotrexate | Methotrexate Sodium | 258 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 70 |
| Simvastatin | Simvastatin | 243 | 63 |
| Losartan Potassium | Losartan Potassium | 238 | 65 |
| Allopurinol | Allopurinol | 226 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 221 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 51 |
| Omeprazole | Omeprazole | 180 | 51 |
| Celecoxib | Celecoxib | 174 | 48 |
| Oxycodone Hcl | Oxycodone Hcl | 173 | 20 |
| Eliquis | Apixaban | 169 | 42 |
| Tramadol Hcl | Tramadol Hcl | 161 | 32 |
| Pregabalin | Pregabalin | 146 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 145 | 13 |
| Trazodone Hcl | Trazodone Hcl | 138 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 29 |
| Meloxicam | Meloxicam | 117 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 26 |
| Lorazepam | Lorazepam | 95 | 34 |
| Furosemide | Furosemide | 88 | 21 |
| Metformin Hcl | Metformin Hcl | 88 | 22 |
| Alprazolam | Alprazolam | 87 | 23 |
| Atenolol | Atenolol | 86 | 25 |
| Sertraline Hcl | Sertraline Hcl | 81 | 25 |
| Humira(Cf) Pen | Adalimumab | 78 | 11 |
| Metformin Hcl Er | Metformin Hcl | 75 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 20 |
| Ibuprofen | Ibuprofen | 71 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 14 |
| Jardiance | Empagliflozin | 64 | 13 |
| Diazepam | Diazepam | 63 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 16 |
| Etodolac | Etodolac | 58 | 16 |
| Colchicine | Colchicine | 57 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 55 | suppressed |
| Xarelto | Rivaroxaban | 54 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 23 |
| Donepezil Hcl | Donepezil Hcl | 53 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 14 |
| Enbrel | Etanercept | 47 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 45 | 17 |
| Synthroid | Levothyroxine Sodium | 45 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 17 |
| Leflunomide | Leflunomide | 38 | 14 |
| Mirtazapine | Mirtazapine | 38 | 13 |
| Xeljanz Xr | Tofacitinib Citrate | 38 | suppressed |
| Sulfasalazine | Sulfasalazine | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Enbrel Sureclick | Etanercept | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Nabumetone | Nabumetone | 29 | 11 |
| Potassium Chloride | Potassium Chloride | 29 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Orencia Clickject | Abatacept | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Rinvoq | Upadacitinib | 23 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Ozempic | Semaglutide | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Actemra Actpen | Tocilizumab | 15 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Humira | Adalimumab | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $232.20 · 10 records | E.R. Squibb & Sons, L.L.C. | AREXVY, CAMZYOS, CAPVAXIVE, ELIQUIS, EVENITY, GARDASIL 9, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error